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The objective of the present study was to identify sperm abnormalities in young male patients with juvenile dermatomyositis
(JDM). In 2005, 18 male JDM patients, diagnosed according to the criteria of Bohan and Peter, were followed at the Pediatric
Rheumatology Unit and Rheumatology Division, of our Institution. Of the 18 males, 11 were pre-pubertal and 7 were post-
pubertal. Two of 7 post-pubertal JDM male patients were excluded: one for orchidopexy for cryptorchidism and the other for
testicular ectopia in the left testis. The remaining 5 post-pubertal JDM patients were prospectively evaluated on the basis of two
semen analyses, according to the World Health Organization (WHO), urologic evaluation, testicular Doppler ultrasound
hormone profile. The data of the JDM patients were compared with those of 5 age-matched healthy controls. The median age
18, was similar in JDM patients and controls. All JDM patients had teratozoospermia (abnormal sperm morphology), as did 4
(80%) of the controls. One of JDM patients had previous oligoasthenoteratozoospermia treated with intravenous cyclophospha-
mide with normalization of the number and concentration of the sperm after 5 years. All sperm parameters (sperm concentration,
total sperm count and total motile sperm count by WHO, and sperm morphology by Kruger strict criteria), testicular volumes by
Prader orchidometer and ultrasound, and hormones were similar in JDM patients compared with controls. The frequency of anti-
sperm antibodies was similar in both groups. All JDM patients had minor sperm abnormalities in the head, midpiece, and/or tail
of spermatozoids. Serial semen analyses in larger study populations are necessary to identify the extent and duration of sperm
abnormalities in male patients with idiopathic inflammatory myopathies.
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Introduction
Juvenile dermatomyositis (JDM) is a rare multisystemic
disease affecting 2 to 4 children per million, particularly
males, characterized by vasculitis that affects the skin and
muscles (1). Survival and prognosis for patients with JDM
have improved in the last decades. JDM patients are living
longer and clinical attention has begun to shift toward
improving their quality of life. Upon becoming adolescents
and young adults, male JDM patients are often concerned
about their future fertility. Evaluation of young male go-
nadal function requires a complete urological examination
in order to determine minor or major sperm alterations due
to age, genital system abnormalities [e.g., hydrocele, hy-
pospadia, cryptorchidism, testicular infection (e.g., mumps),
testicular cancer], influence of drugs especially intrave-
nous cyclophosphamide (IVCYC), and antisperm antibodies
(2). Of note, we recently identified sperm abnormalities in
young (2,3) and adult male systemic lupus erythematosus
(SLE) patients associated with IVCYC treatment (4).
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In JDM, disease activity may be an additional contribut-
ing factor for possible testicular damage, supported by the
report of one case of testicular vasculitis in a 7-year-old
boy (5). However, there is no systematic study assessing
the overall gonad function in young male JDM patients and
its relevance for sperm abnormalities.
The objective of this study was to perform a global
testicular assessment in post-pubertal male JDM patients
and a matched control group.
Subjects and Methods
In 2005, 18 male JDM patients, diagnosed according to
Bohan and Peter criteria (6), were followed at the Pediatric
Rheumatology Unit and at the Rheumatology Division, of
our institution. Eleven were pre-pubertal and 7 were post-
pubertal. Exclusion criteria were hydrocele, hypospadia,
cryptorchidism, testicular infection (e.g., mumps), testicu-
lar cancer, orchitis, testicular vasculitis, urethral impair-
ment, previous history of any scrotal or inguinal surgery
(e.g., varicocelectomy, vasectomy, hernia repair), diabe-
tes mellitus, previous or current history of alcohol or to-
bacco use, and refusal to collect sperm sample or incom-
plete evaluation. Two of 7 post-pubertal JDM male patients
were excluded due to orchidopexy for cryptorchidism in
one and testicular ectopia in the left testis in the other. The
remaining 5 JDM patients were compared with a control
group of 5 age-matched healthy male adolescents regu-
larly followed at the Adolescent Unit. The Local Ethics
Committee approved this study, and written informed con-
sent was obtained from all participants or from a parent, if
necessary.
An extensive clinical evaluation by the same rheuma-
tologist was followed by a careful chart review including
previous clinical, laboratory, and treatment-related data.
JDM manifestations were defined as cutaneous lesions
(heliotrope, Gottron’s papules, vasculitis, calcinosis, ulcer-
ative skin or malar rash), articular involvement (arthralgia
or nonerosive arthritis), muscular involvement (muscle
weakness, muscle edema), cardiopulmonary disease (se-
rositis, myocarditis, restrictive lung disease, and pulmo-
nary hypertension), and intestinal involvement (dysphagia
or vasculitis). JDM disease activity and damage were
measured in all patients using the following tests: Child-
hood Health Assessment Questionnaire (CHAQ) (7),
Manual Muscle Testing (8), Childhood Myositis Assess-
ment Scale (CMAS) (9), and Disease Activity Score (DAS)
(10). Physician and patient assessments of global disease
activity and damage were rated on a 10-cm visual analog
scale (VAS) (11) and physical functioning was assessed
by the Medical Outcomes Study 36 Item Short-Form Health
Survey (PF-SF-36) (12). Data about the period of therapy
(pre-pubertal or post-pubertal) were collected as well as
current dosage and cumulative doses of drugs (pred-
nisone, chloroquine diphosphate, methotrexate, azathio-
prine, cyclosporine, colchicine, and IVCYC). The time and
duration of IVCYC therapy were also determined.
A systematic clinical examination of the genitalia was
performed on patients and controls by the same expert
urologist and included evaluation of testicles, epididymis,
vas deferens, scrotum, and penis. The secondary sexual
characteristics were evaluated according to Tanner’s pat-
tern criteria of pubertal changes (13). Testicular volume
was measured using Prader orchidometry, which consists
of 12 ellipsoid models graded from 1 to 25 mL (1-6, 8, 10,
12, 15, 20, and 25) (14). The patients were examined in a
warm room with temperature not <22°C, in both the stand-
ing and supine positions, and with and without Valsalva
maneuver. Varicocele was graded according to the follow-
ing criteria: grade I (small) = palpable only with concurrent
Valsalva maneuver; grade II (medium) = palpable with
patient standing, and grade III (large) = visible through
scrotal skin, palpable with patient standing (15). Ultra-
sound was performed on all JDM patients and control
subjects by an expert sonographer who used a 14-MHz
sector scanner (Logic 9; GE, USA) and who was not aware
of the results of the semen analysis. Testes were scanned
in axial and longitudinal planes, and at least 2 measure-
ments of length, width, and thickness were obtained. The
largest measurement in each dimension was recorded and
used to calculate the testicular volume according to the
formula for an ellipsoid (length x width x thickness x 0.52).
The mean ± SD value for normal male post-pubertal ado-
lescents and adults is 15 ± 8 mL (15).
Semen analysis was performed according to the guide-
lines of the World Health Organization (WHO) (16) by 2
expert medical technologists who were not aware of dis-
ease diagnosis. Within 1 month after acceptance into the
study, all JDM patients and controls were asked to provide,
after 48-72 h of sexual abstinence, 2 semen samples,
which were collected by masturbation in the laboratory
collection room and processed within 1 h of liquefaction.
Semen specimens were liquefied at 37°C for 30 min, and
sperm concentration and motility were measured manually
with a microscope fitted with a 20-X positive phase-con-
trast objective and an overall magnification of 200X. Micro-
scopic images were transferred through a video system to
a computer-assisted semen analyzer attached to the opti-
cal microscope and were digitized according to a software
program. The specimens were analyzed by manual hand
count as well as by a computer-assisted semen analysis
system under 400X magnification (HTM-2030 motility ana-
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lyzer, Hamilton Thorne Research, USA). Each slide was
scanned to estimate the number of spermatozoa per field
equivalent to 1 mL to obtain an approximate sperm con-
centration reported in millions of spermatozoa per milliliter
semen. Sperm motility was determined by analysis of at
least 5 microscopic fields in a systematic manner to clas-
sify 200 spermatozoa. The motility of each spermatozoon
was graded “a” (rapid progressive motility) and “b” (slow or
sluggish progressive motility). Sperm morphology included
evaluation of sperm head, neck, midpiece, and tail by 2
medical technologists who were not aware of disease
diagnosis. A patient was considered to have azoospermia
when no spermatozoa were found in the ejaculate (16).
Oligozoospermia was defined as a sperm concentration
<20 million/mL. Asthenozoospermia was defined as nor-
mal sperm motility (“a” + “b”) in <50% of spermatozoa.
Teratozoospermia was defined as normal sperm morphol-
ogy in <30% of spermatozoa by WHO criteria, and
oligoasthenoteratozoospermia was defined as an altera-
tion in all 3 variables. Sperm morphology was additionally
evaluated according to Kruger strict criteria, in which <14%
normal morphology is associated with subfertility (17).
The presence of antisperm antibodies was determined
by direct Immunobead test using Immunobead rabbit anti-
human Ig (IgA, IgG, and IgM) kits (Irvine Scientific, USA).
The direct Immunobead binding test detects antibodies
that bind to the sperm cell surface (sperm head, midpiece,
and/or tail). At least 50% of the motile spermatozoa (“a” +
“b”) must be coated with Immunobeads before the test
results are considered to be clinically significant (16). Quality
control was carried out as recommended by the manufac-
turer (Irvine Scientific, USA). A negative control should have
a score of <10% bead attachment, and a positive control
should have a score >20% bead attachment.
Hormone determinations were performed at study en-
try. Follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), prolactin, total testosterone, triiodothyronine
(T3), tetraiodothyronine (T4), free tetraiodothyronine (free
T4), and thyrotropin (TSH) were evaluated by fluoroimmu-
noassay using DELFIA time-resolved fluoroimmunoassay
kits (Wallac, Finland). Intra- and interassay coefficients of
variation were limited to 3.5 and 2.1%, respectively.
Data were compared by the t-test or by the Mann-
Whitney U-test for continuous variables to evaluate differ-
ences between the JDM patients and the control group. P
values less than 0.05 were considered to be significant.
Results
The clinical features, laboratory exams, previous and
current therapy in 5 male JDM patients are reported in
Table 1. All patients had normal CMAS, DAS, CHAQ, and
PF-SF-36 scores. Disease activity was observed in 2 JDM
patients: patients 2 and 3 had higher scores of DAS, VAS
as reported by the patient, and VAS as reported by the
physician (2 and 5, 3 and 5, 4 and 5, respectively). All
patients received drugs after puberty with the exception of
2 who were treated with steroid, chloroquine diphosphate
and colchicine therapies in the pre-pubertal period.
The medians of current age and age of first ejaculation
were similar in JDM patients and controls [18 years (range
16-22) vs 18 years (range 16-22), P = 1.0, and 13 years
(range 13-14) vs 13 years (range 12-15), P = 0.785,
respectively]. All JDM patients and controls were classified
as P5 and G5, respectively, according to sex maturity
states by Tanner’s pattern criteria of pubertal changes
(13). The median values of the testicular volumes in both
testes according to Prader orchidometry were similar in
JDM patients and controls (20 vs 20 mL in the right testicle,
and 20 vs 20 mL in the left testicle, respectively). The
medians of the testicular volumes in both testes according
to ultrasound were homogeneous in JDM patients and
controls (10.6 vs 11.7 mL in the right testicle, and 10.2 vs
10.5 mL in the left testicle, respectively). In addition, 2 JDM
patients and 2 controls had varicocele grade I (40 vs 40%).
All JDM patients and controls had normal testicular vol-
umes by ultrasound and Prader orchidometry.
All 5 JDM patients (100%) had teratozoospermia (ab-
normal sperm morphology in the head, midpiece, and/or
tail of spermatozoids), as did 4 controls (80%, P = 1.0).
Remarkably, one of the JDM patients (case 4) had previ-
ous oligoasthenoteratozoospermia (low sperm concentra-
tion, motility and morphology) with IVCYC treatment [14
monthly infusions with 500 mg/m2 and a cumulative dose
of 6.6 g (150 mg/kg)] with normalization of the number and
concentration of sperm after 5 years. No patient had
azoospermia.
The mean of 2 sperm analyses in JDM patients was
compared with controls. No significant differences were
found between JDM patients and controls in median sexual
abstinence and sperm volume (3.5 vs 3.4 days, P = 0.564,
and 2.8 vs 2.4 mL, P = 0.465, respectively). Likewise, no
significant difference was observed in median sperm pH
(7.7 vs 7.5; P = 0.059). The microscopic investigation
showed that JDM patients had median sperm concentra-
tions (50 x 106/mL vs 60.5 x 106/mL; P = 0.5), total sperm
count (212 x 106/mL vs 120 x 106/mL; P = 0.5) and total
motile sperm count (74 x 106/mL vs 70 x 106/mL; P = 0.893)
similar to controls. Assessment of sperm morphology by
Kruger strict criteria demonstrated similar median normal
sperm forms in JDM patients and controls (5.0 vs 4.5%; P
= 0.715) as also observed by the WHO criteria (19 vs 18%;
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Table 1. Demographic data, clinical features, laboratory exams, previous and current therapy in 5 male juvenile dermatomyositis patients.
Variables Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age at disease onset 9 years 3 years 13 years 15 years 6 years
Disease duration at 8 years 13 years 7 years 7 years 12 years
study entry
JDM clinical Muscle weakness, Severe muscle weakness, Severe muscle Severe muscle Muscle weakness,
manifestation and heliotrope, heliotrope, weakness, heliotrope, weakness, heliotrope, pyrexia, heliotrope,
laboratory exams Gottron’s papules, Gottron’s papules, Gottron’s papules, Gottron’s papules, Gottron’s papules,
↑muscle enzymes calcinosis, pyrexia, weight loss,  dysphagia, pyrexia, weight loss, fatigue,
↑muscle enzymes  ulcerative skin, duodenal vasculitis, ↑muscle enzymes
calcinosis, ↑muscle enzymes
↑muscle  enzymes
Cumulative dose (g)
PRED 8.68 31.4 9.4 25.6 16.2
IVCYC 0 0 0 6.6 0
MTX 0 0.16 0.465 0 0
AZA 0 0 0 71.2 0
CD 0 72 487.5 30 0
COL 0 0 0 0 0.78
Current medication - PRED 10 mg/day PRED 30 mg/day - -
MTX 15 mg/week - -
CD 50 mg/day - -
PRED = prednisone; IVCYC = intravenous cyclophosphamide; MTX = methotrexate; AZA = azathioprine; CD = chloroquine diphosphate; COL =
colchicine.
P = 0.893). Of note, one of the JDM patients with cutane-
ous active disease had anti-sperm antibodies (>20%) in
the spermatozoon mid-piece and none of the controls had
the presence of these antibodies (1.0).
All JDM patients and controls had normal hormone
profiles. No significant differences were found between the
medians in the 2 groups: FSH (3.3 vs 3.6 IU/L; P = 0.686),
LH (3.7 vs 3.7 IU/L; P = 0.893), prolactin (7.1 vs 6.4 ng/mL;
P = 0.500), total testosterone (394 vs 677 ng/dL; P =
0.138), T4 (8.9 vs 9.3 µg/dL; P = 0.893), free T4 (1.3 vs 1.2
ng/dL; P = 0.684), and TSH (2.1 vs 2.2 µU/mL; P = 0.686).
The median T3 levels were significantly higher in JDM
patients compared with controls (152 vs 140 ng/dL; P =
0.043); however, these levels are normal for these hor-
mones.
Discussion
This is the first systematic evaluation that has specifi-
cally addressed sperm abnormalities in post-pubertal JDM.
Despite a very small sample size, we evaluated a control
population and demonstrated minor semen alterations in
both groups. Remarkably, one of our patients had previ-
ously severe sperm abnormalities during IVCYC use.
An advantage of our study was in using established
worldwide definitions for semen alterations. Teratozoo-
spermia was observed in 100% of JDM patients and 80%
of controls. These patients and controls could be classified
as subfertile concerning the cutoff values for normality in 2
conventional techniques of semen morphology. Moreover,
Mori et al. (18) studied 127 healthy adolescents (age, 14-
20 years) in the city of São Paulo and observed
teratozoospermia in 82% of the adolescents who were
classified as P5 and G5 according to Tanner’s pattern
criteria of pubertal changes (13). Likewise, an Italian study
evaluated 25 healthy adolescents who were 14 to 18 years
old and observed a prevalence of abnormal forms of
spermatozoon in 56% (19). Remarkably, we recently stud-
ied gonad evaluation in 35 male adolescents and adult
SLE patients and 35 controls paired by age. Teratozoo-
spermia was observed in 100% of SLE patients vs 85% of
controls (7), similar to that observed here for our young
male JDM patients. All adult controls with teratozoospermia
fathered children. Furthermore, regional differences in se-
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men morphology, possibly associated with environmental
exposures or lifestyle, may explain the teratozoospermia,
as has been reported in the United States (20).
Testicular volume assessment is of utmost importance
when evaluating gonadal function due to the fact that
seminiferous tubules represent 95% of the testis volume. It
is very important to perform a testicular ultrasound to rule
out varicocele, even when testicular volume is normal (15).
In our study, testicular volume was normal in all patients
and controls, grade I varicocele was observed in one
patient and in one control with normal testis volume. Al-
though varicocele is believed to be one of the most com-
mon causes of male subfertility, grade I varicocele has no
detectable sperm abnormalities and dysfunction of the
hypothalamic-pituitary-testicular axis (2). FSH is the major
marker of seminiferous epithelium function, and high lev-
els suggest definitive testicular damage (2). All our pa-
tients had normal hormone levels reinforcing that male
JDM patients had normal gonadal function.
A possible role of antisperm antibodies as a marker for
gonadal dysfunction was seen in 1 patient with active JDM.
Soares et al. (4) showed a higher frequency of these
antibodies in Brazilian SLE patients with teratozoospermia
(56%) versus SLE with azoospermia or oligoasthenotera-
tozoospermia (24%), with the same methodology as the
present study.
The testis is susceptible to the toxic effects of IVCYC
therapy, which might produce long-lasting or persistent
damage to primordial sperm cells, leading to oligoastheno-
teratozoospermia in patients with juvenile SLE (2,3) or
SLE (4). Indeed, sperm cryopreservation should be dis-
cussed as a routine part of therapeutic management to
preserve fertility in patients who will receive IVCYC (2).
We have shown here that JDM patients had minor
sperm abnormalities. Serial semen analyses in larger study
populations are necessary to determine the degree and
duration of sperm abnormalities in male patients with idio-
pathic inflammatory myopathies, particularly associated
with immunosuppressive drugs.
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